{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"acquired-partial-lipodystrophy","columns":[{"gene":"","key":"population-4bab23120a5a6e92bbe9","label":"Acquired partial lipodystrophy","mondoId":"MONDO:0012104","onsetQualifier":null,"originColumnKey":"MONDO:0012104/ORPHA:79087","originalViews":[{"key":"MONDO:0012104/ORPHA:79087","label":"Acquired partial lipodystrophy","scopeLabel":"ORPHA:79087","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["111abab5e120d742e969a6c98fb4cd43926f5d21224baaa405769c6b75e544b1","17132b41db390c2525c7d51c4df34cfed40f170f9beafffc1ee41080ab2c702f","1c18de801c4701fa075361fba89b55dc7de2362af5056b526fe9cd2a2fb6c1e7","2193a1bbb717f3c8390ba21fc65665d63084d8b3cf23c69168bf17ee25f9025c","2bb52d3cf2106c9ac046c7de718f345395ef90edde6e2e5c18d692a8af31b103","4e916d46d70b3aae290da15d78952b7cc90ce9e1c6bb4782e3d6b87216b9c6ee","5229a8312b26166987f6e9590af9c591ae24bf3d0db428aa6b4138597af8ab50","6ac36738d80edbcfb4ab93c469f0b34984798bd91008315c1ef44435a88afb46","70af00aac3910749af8effc302d7b63cfda6007e0f8342cb48e22c93426c7fe2","bb84dcf02350f22be1594d850db067b6732dcff52b7ea121114678d80475283a","c562c385f008252f6710d77a426456de3a3315dc55182830cbdc1928edbcb96a","c5811dbe2d04b8bdf353c79cd012f7ee5b44e8dd738abd297873e8b123654480","ccd617321a7f44187b9ad537f965f1637fd50666b7f54ce5a3867d6fcfa4718d","d00e469391e66b8426f853e7628670e53d8adafbb2edfa96bbf57742402bb18a","e0dc2ce5d6a517890cd33cf20cd212ea3fdd1c97f7aa7bd3adb361bf27228180","f83fd3f88654f5d4e9230b61f3201846daa415329d3966c408a8d85ca32b68a8","fdcb8b76ab952489bdead59545f543f4808e2c66dc8a3e2515602bbbee9d4774"],"recordQualifiers":{},"scopeLabel":"ORPHA:79087","sourceIds":["ORPHA:79087"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-4bab23120a5a6e92bbe9"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0002829","HP:0002960","HP:0005421","HP:0002230","HP:0100820","HP:0000365","HP:0001397"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":17,"sourceGroups":{"orphanet":17}},"features":[{"hpoId":"HP:0002829","label":"Arthralgia","primary":true},{"hpoId":"HP:0002960","label":"Autoimmunity","primary":true},{"hpoId":"HP:0005421","label":"Decreased circulating complement C3 concentration","primary":true},{"hpoId":"HP:0002230","label":"Generalized hirsutism","primary":true},{"hpoId":"HP:0100820","label":"Glomerulopathy","primary":true},{"hpoId":"HP:0000365","label":"Hearing impairment","primary":true},{"hpoId":"HP:0001397","label":"Hepatic steatosis","primary":true},{"hpoId":"HP:0002721","label":"Immunodeficiency","primary":false},{"hpoId":"HP:0100827","label":"Increased total lymphocyte count","primary":false},{"hpoId":"HP:0000855","label":"Insulin resistance","primary":false},{"hpoId":"HP:0001249","label":"Intellectual disability","primary":false},{"hpoId":"HP:0100578","label":"Lipoatrophy","primary":false},{"hpoId":"HP:0002907","label":"Microscopic hematuria","primary":false},{"hpoId":"HP:0003198","label":"Myopathy","primary":false},{"hpoId":"HP:0005328","label":"Progeroid facial appearance","primary":false},{"hpoId":"HP:0000093","label":"Proteinuria","primary":false},{"hpoId":"HP:0001250","label":"Seizure","primary":false}],"ledeHtml":"Barraquer-Simons syndrome, or acquired partial lipodystrophy, is characterized by the loss of fat from the face, neck, shoulders, arms, forearms, chest and abdomen. Occasionally the groin or thighs are also affected. Onset usually begins in childhood following a viral illness. It affects females more often than males. Following puberty, affected women may experience a disproportionate accumulation of fat in the hips and lower limbs. Around 1 in 5 people with this syndrome develop membranoproliferative glomerulonephritis. This kidney condition usually develops more than 10 years after the lipodystrophy&#x27;s onset. Autoimmune disorders may also occur in association with this syndrome.","mondoId":"MONDO:0012104","node":{"canonicalSlug":"acquired-partial-lipodystrophy","comparisons":[{"documentSha256":"07458c44689152267f1474d8f25159857ffb64ab39073ac00b987c18f68ee388","key":"legacy-acquired-lipodystrophy","kind":"legacy","label":"acquired lipodystrophy","memberIds":["MONDO:0012104","MONDO:0019193","MONDO:0020089"],"mondoId":"MONDO:0020089","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/acquired-lipodystrophy.07458c44689152267f1474d8f25159857ffb64ab39073ac00b987c18f68ee388.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"Acquired partial lipodystrophy","originalSourceId":"ORPHA:79087","paragraphs":["Barraquer-Simons syndrome, or acquired partial lipodystrophy, is characterized by the loss of fat from the face, neck, shoulders, arms, forearms, chest and abdomen. Occasionally the groin or thighs are also affected. Onset usually begins in childhood following a viral illness. It affects females more often than males. Following puberty, affected women may experience a disproportionate accumulation of fat in the hips and lower limbs. Around 1 in 5 people with this syndrome develop membranoproliferative glomerulonephritis. This kidney condition usually develops more than 10 years after the lipodystrophy's onset. Autoimmune disorders may also occur in association with this syndrome."],"rawAttribution":"MONDO:0012104","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-25T03:41:09Z","upstream":"GARD:0010509","url":"https://rarediseases.info.nih.gov/diseases/10509"},"ownColumnKeys":["population-4bab23120a5a6e92bbe9"],"publication":"published","relationships":[{"kind":"parent","label":"acquired lipodystrophy","mondoId":"MONDO:0020089","slug":"acquired-lipodystrophy"},{"kind":"parent","label":"partial lipodystrophy","mondoId":"MONDO:0027767","slug":"partial-lipodystrophy"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"published"},"records":[{"frequencyKind":"range","key":"111abab5e120d742e969a6c98fb4cd43926f5d21224baaa405769c6b75e544b1","raw":{"aspect":"P","body_system":"other","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002829","is_excluded":false,"label":"Arthralgia","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"17132b41db390c2525c7d51c4df34cfed40f170f9beafffc1ee41080ab2c702f","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0100820","is_excluded":false,"label":"Glomerulopathy","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"1c18de801c4701fa075361fba89b55dc7de2362af5056b526fe9cd2a2fb6c1e7","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0005328","is_excluded":false,"label":"Progeroid facial appearance","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"2193a1bbb717f3c8390ba21fc65665d63084d8b3cf23c69168bf17ee25f9025c","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0100827","is_excluded":false,"label":"Increased total lymphocyte count","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"2bb52d3cf2106c9ac046c7de718f345395ef90edde6e2e5c18d692a8af31b103","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0003198","is_excluded":false,"label":"Myopathy","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"4e916d46d70b3aae290da15d78952b7cc90ce9e1c6bb4782e3d6b87216b9c6ee","raw":{"aspect":"P","body_system":"immune","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0005421","is_excluded":false,"label":"Decreased circulating complement C3 concentration","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"5229a8312b26166987f6e9590af9c591ae24bf3d0db428aa6b4138597af8ab50","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000855","is_excluded":false,"label":"Insulin resistance","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"6ac36738d80edbcfb4ab93c469f0b34984798bd91008315c1ef44435a88afb46","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0100578","is_excluded":false,"label":"Lipoatrophy","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"70af00aac3910749af8effc302d7b63cfda6007e0f8342cb48e22c93426c7fe2","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002907","is_excluded":false,"label":"Microscopic hematuria","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"bb84dcf02350f22be1594d850db067b6732dcff52b7ea121114678d80475283a","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000093","is_excluded":false,"label":"Proteinuria","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"c562c385f008252f6710d77a426456de3a3315dc55182830cbdc1928edbcb96a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001250","is_excluded":false,"label":"Seizure","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"c5811dbe2d04b8bdf353c79cd012f7ee5b44e8dd738abd297873e8b123654480","raw":{"aspect":"P","body_system":"immune","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002960","is_excluded":false,"label":"Autoimmunity","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"ccd617321a7f44187b9ad537f965f1637fd50666b7f54ce5a3867d6fcfa4718d","raw":{"aspect":"P","body_system":"ear","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000365","is_excluded":false,"label":"Hearing impairment","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d00e469391e66b8426f853e7628670e53d8adafbb2edfa96bbf57742402bb18a","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001397","is_excluded":false,"label":"Hepatic steatosis","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"e0dc2ce5d6a517890cd33cf20cd212ea3fdd1c97f7aa7bd3adb361bf27228180","raw":{"aspect":"P","body_system":"immune","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002721","is_excluded":false,"label":"Immunodeficiency","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"f83fd3f88654f5d4e9230b61f3201846daa415329d3966c408a8d85ca32b68a8","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001249","is_excluded":false,"label":"Intellectual disability","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"fdcb8b76ab952489bdead59545f543f4808e2c66dc8a3e2515602bbbee9d4774","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:79087","disease_name":"Acquired partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002230","is_excluded":false,"label":"Generalized hirsutism","onset_id":null,"reference":"ORPHA:79087","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/10509\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0012104\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>GARD:0010509</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Barraquer-Simons syndrome, or acquired partial lipodystrophy, is characterized by the loss of fat from the face, neck, shoulders, arms, forearms, chest and abdomen. Occasionally the groin or thighs are also affected. Onset usually begins in childhood following a viral illness. It affects females more often than males. Following puberty, affected women may experience a disproportionate accumulation of fat in the hips and lower limbs. Around 1 in 5 people with this syndrome develop membranoproliferative glomerulonephritis. This kidney condition usually develops more than 10 years after the lipodystrophy&#x27;s onset. Autoimmune disorders may also occur in association with this syndrome.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/10509\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"acquired-partial-lipodystrophy","sourceDocuments":[{"name":"GARD: Acquired partial lipodystrophy","reviewed":null,"source_release":"2026-10-25T03:41:09Z","url":"https://rarediseases.info.nih.gov/diseases/10509"},{"name":"MONDO: acquired partial lipodystrophy","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0012104"}],"sourceNote":"","synonyms":["acquired partial lipodystrophy","APLD","Barraquer-Simons syndrome","lipodystophy partial progressive","lipodystrophy cephalothoracic type","lipodystrophy partial acquired","lipodystrophy, partial, acquired, susceptibility to","partial acquired lipodystrophy","progressive cephalothoracic lipodystrophy"],"takeawayHtml":"","title":"acquired partial lipodystrophy"},"schemaVersion":1}
